Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DMAC vs COCP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DMAC Captures Overall Composite Edge (46.3 HOLD vs 47.1 HOLD), While COCP Leads 3–2 on Growth & Valuation Pillars
DMAC Overall Winner
6-Pillar Tally: DMAC 2 – 3 COCP (1 Tie)
Matrix Metrics: DMAC 4 – 3 COCP
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (46.3/100 HOLD vs. 47.1/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality, Options & Positioning), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.41 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.00 (N/M Forward P/E, -3063.6% operating margin).
- Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3063.6% operating margin) and revenue trajectory (+0.0% vs. +26.9% YoY).
- Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile COCP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DMAC vs COCP
DMAC
Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
$8.41
-4.27% 1D
Market Cap
$503.1M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.74β · 98% Vol
Unified Composite Score
46.3
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
COCP
Cocrystal Pharma, Inc. Common Stock
$1.00
+1.98% 1D
Market Cap
$19.6M
TTM Revenue
$330,000
Forward P/E
N/M
Beta / 30D Vol
1.04β · 54% Vol
Unified Composite Score
47.1
HOLD
Tech 51.0
Fund 48.0
Flow 50.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (DMAC 2 – 3 COCP)
1. Valuation Multiples
COCP
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
49.7x
2. Growth & Scale
COCP
Revenue Growth (YoY)
+0.0%
+26.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$330,000
Market Cap
$503.1M
$19.6M
3. Profitability & Quality
DMAC
Gross Margin
N/A
N/A
Operating Margin
0.0%
-3063.6%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-114.6%
-311.7%
4. Balance Sheet & Cash Flow
COCP
Cash Generation (TTM)
-$32M
-$7.6M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$4.9M Net Cash
$3.3M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DMAC
Options Structure Phase
SURGE
UNCLASSIFIED
Current IV / %ile
106.3% (14th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DMAC (4) vs COCP (3)| Institutional Metric | DMAC | COCP | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $503.1M | $19.6M | DMAC | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | +26.9% | COCP | |
| Operating Margin (TTM) | 0.0% | -3063.6% | DMAC | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -114.6% | -311.7% | DMAC | |
| 52-Week Range Position | 55% ($5–$11) | 19% ($1–$2) | DMAC | |
| Beta / 30D Volatility | 1.74β · 98% Vol | 1.04β · 54% Vol | COCP | |
| Unified Institutional Score | 46.3 / 100 (HOLD) | 47.1 / 100 (HOLD) | COCP | |
| Trailing 12M Revenue (USD) | N/A | $330,000 | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 49.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$32M ($4.9M Net Cash) | -$7.6M ($3.3M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DMAC +13.17 pp
3M Horizon
DMAC +34.76 pp
6M Horizon
DMAC +63.45 pp
1Y Horizon
DMAC +58.22 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | COCP Revenue | DMAC Op. Margin | COCP Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2011 | N/A | $10M | N/A | -30.6% | COCP |
| FY2018 | $0M | N/A | -1352.2% | N/A | DMAC |
| FY2019 | N/A | $10M | N/A | -737.4% | COCP |
| FY2020 | N/A | $0M | N/A | -476.0% | COCP |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DMAC
SURGE
Current IV
106.3%
IV Percentile
14th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
COCP
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DMAC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
COCP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DMAC vs COCP Key Questions & Quantitative Answers
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (46.3/100 HOLD vs. 47.1/100 HOLD) after splitting the core matrix 4–3 (led by Profitability & Quality, Options & Positioning), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.41 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.00 (N/M Forward P/E, -3063.6% operating margin). Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3063.6% operating margin) and revenue trajectory (+0.0% vs. +26.9% YoY). Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile COCP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
COCP leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). Across the 4-period historical trajectory (FY2011 to FY2020), DMAC cumulative revenue shifted N/A while COCP shifted +0.0%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.
COCP screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus COCP (-311.7% ROE) capital efficiency.
In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
COCP vs DMAC · Reverse Pair
DMAC vs TRVI
· Sector Peer
DMAC vs VRCA
· Sector Peer
DMAC vs FENC
· Sector Peer
COCP vs PRPO
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma